Ovarian Failure, Premature
|
0.020 |
Biomarker
|
disease |
BEFREE |
MATER (maternal antigen that embryos require) is a known ovarian autoantigen targeted in autoimmune syndromes of POI.
|
21447630 |
2011 |
Ovarian Failure, Premature
|
0.020 |
Biomarker
|
disease |
LHGDN |
Characterization of the human MATER and its protein provides a basis for investigating their clinical implications in autoimmune premature ovarian failure and infertility in women.
|
11925379 |
2002 |
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Most interesting was the finding that the enigmatic development-related NLRP5 (also known as MATER) was not expressed in normal colon tissue but in colon cancer tissue and cell lines.
|
29928061 |
2018 |
Endometritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The "RESEAU MATER": An efficient infection control for endometritis, but not for urinary tract infection after vaginal delivery.
|
27592614 |
2018 |
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Most interesting was the finding that the enigmatic development-related NLRP5 (also known as MATER) was not expressed in normal colon tissue but in colon cancer tissue and cell lines.
|
29928061 |
2018 |
Multiple Sclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In addition, PSMG4 p.W99R and NLRP5 p.R761L were found to correlate with an earlier age at MS clinical onset, and MC1R p.R160W with delayed onset of clinical symptoms (p=0.010-0.041).
|
28501589 |
2017 |
Progressive Neoplastic Disease
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
CACNA1H p.R1871Q was found associated with patients presenting relapsing remitting MS at clinical onset (p=0.028) whereas NLRP5 p.M459I and EIF2AK1 p.K558R were associated with primary progressive disease (p=0.031 and 0.023).
|
28501589 |
2017 |
Progressive cGVHD
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CACNA1H p.R1871Q was found associated with patients presenting relapsing remitting MS at clinical onset (p=0.028) whereas NLRP5 p.M459I and EIF2AK1 p.K558R were associated with primary progressive disease (p=0.031 and 0.023).
|
28501589 |
2017 |
Developmental delay (disorder)
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Offspring of mothers with NLRP5 mutations have heterogenous clinical and epigenetic features, but cases include a discordant monozygotic twin pair, individuals with idiopathic developmental delay and autism, and families affected by infertility and reproductive wastage.
|
26323243 |
2015 |
Global developmental delay
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Offspring of mothers with NLRP5 mutations have heterogenous clinical and epigenetic features, but cases include a discordant monozygotic twin pair, individuals with idiopathic developmental delay and autism, and families affected by infertility and reproductive wastage.
|
26323243 |
2015 |
Autoimmune Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Transgenic expression of MATER in APC can induce antigen-specific tolerance with a significant reduction in ovarian autoimmunity.
|
21447630 |
2011 |
Polyglandular Type I Autoimmune Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
As a known autoantigen in the human APS1 (autoimmune polyglandular syndrome type 1), which is associated with POI, MATER may represent a relevant target for future diagnostic and therapeutic clinical interventions.
|
21447630 |
2011 |
Hypoparathyroidism
|
0.010 |
Biomarker
|
disease |
LHGDN |
Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen.
|
18322283 |
2008 |
Infertility
|
0.010 |
Biomarker
|
phenotype |
LHGDN |
Characterization of the human MATER and its protein provides a basis for investigating their clinical implications in autoimmune premature ovarian failure and infertility in women.
|
11925379 |
2002 |